Comparing the efficiency and occurrence of complications during dual antiplatelet therapy (NOAK + P2Y12 inhibitor) and triple antiplatelet therapy (VKA + P2Y12 inhibitor + Aspirin), results of PIONER AF-PCI studies with rivaroxaban, a RE-DUAL PCI study with dabigatran, AUGUSTUS with apixaban, and ENTRUST-AF PCI with edoxaban were very similar. This evidence concerns the gene P2RY12 and atrial fibrillation.